SecBot SecBot

ELTX

Elicio Therapeutics, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001601485 Biotech & Drug Discovery
$1.70 −0.20 (−10.53%)
Oct 26 4:00 PM ET · prev $1.90
Market cap
$52.6M
Micro cap
Consensus
Buy
80% Buy or better · 10 analysts
Median target
🔒 Subscribers only
Next earnings
Nov 11
in 16 days
1 year
−82.5%
from $9.70 · Oct 27
30 days
−8.1%
from $1.85
52-week range
$1.55–14.85
−89% from high · low Oct 19
Avg volume 20D
295.2K
shares / day
Short interest
1.55M
≈5.9% of shares · −6.8%
Days to cover
4.1
at average volume
Insider net
$0
no open-market trades · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
SecBot read MIXED 2 reports · 90 days
Balance 0 bearish · 0 bullish · 2 neutral oldest → newest, height = score
Avg score ·High conf. 1/2 ·Next Earnings date, Nov 11, 2026
Strongest NEUTRAL Elicio Therapeutics filed its definitive proxy statement for the 2026 Annual Meeting of Stockholders to be…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • InstitutionsBULLISH

    Q2 2026: 7 added (0 new), 1 trimmed or exited.

  • AnalystsBULLISH

    8 of 10 rate it Buy or better.

  • Short sellersSTEADY

    Short interest −6.8% to 1.55M shares. 4.1 days to cover, ≈5.9% of shares.

  • TrendDOWNTREND

    22% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
BlackRock, Inc.DOUBLED766,005$3.0M
GEODE CAPITAL MANAGEMENT, LLCDOUBLED311,354$1.2M
STATE STREET CORPDOUBLED179,420$701.5K
NORTHERN TRUST CORPDOUBLED130,162$508.9K
VANGUARD FIDUCIARY TRUST COADD88,062$344.3K
BNP PARIBAS FINANCIAL MARKETSTRIM2,072$8.1K
Farther Finance Advisors, LLCADD947$3.7K
ROYAL BANK OF CANADADOUBLED443$2.0K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

10 analysts
Buy 80% rate it Buy or better
Strong Buy3Buy5Hold2Sell0Strong Sell0

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access
Recent actions
DateFirmActionRating
Sep 24, 2026B. Riley Securities
MAINTAIN
MAINTAINBuy
Aug 18, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Jun 16, 2026Jones Trading
DOWNGRADE
DOWNGRADEHold
Jun 15, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Jun 10, 2026B. Riley Securities
INITIATE
INITIATEBuy
May 28, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Aug 31, 2026
Ashe Carol Gail
Director
AWARD21,750 sh
Aug 31, 2026
Chudnovsky Yekaterina
Director
AWARD21,750 sh
Aug 31, 2026
Nissenson Allen
Director
AWARD21,750 sh
Aug 31, 2026
RUFFOLO ROBERT R
Director
AWARD21,750 sh
Aug 31, 2026
WILSON KAREN J
Director
AWARD21,750 sh
Aug 31, 2026
Venkatesan Jay
Director
AWARD21,750 sh
Aug 31, 2026
ADAMS JULIAN
Director
AWARD21,750 sh
Jul 16, 2026
Connelly Robert
CEO, President and Director
AWARD186,944 sh

Earnings setup

Estimates
Nov 11
reports in 16 days

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Sep 30, 2026
1,552,675
shares short
-6.8%
vs prior settlement
4.1
days to cover
≈5.9%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 9, 2026 SEC
Elicio Therapeutics filed its definitive proxy statement for the 2026 Annual Meeting of Stockholders to be held on…
DEF 14A — Impact 3/10
Sep 22, 2026 SEC
An institutional cluster in ELTX shows 7 buyers (net +$1.9M) against 1 seller (-$60K), dominated by mega-passive funds…
INST-CLUSTER — Impact 3/10
Aug 31, 2026 Other
Elicio Therapeutics to Participate at the H.C. Wainwright 28th Annual Global Investment Conference
BOSTON, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “
Aug 31, 2026 Insider
Ashe Carol Gail was granted 21,750 shares
Director
Aug 31, 2026 Insider
Chudnovsky Yekaterina was granted 21,750 shares
Director
Aug 31, 2026 Insider
Nissenson Allen was granted 21,750 shares
Director
Jul 2, 2026 SEC
Elicio Therapeutics is raising approximately $13.6 million in net proceeds through a registered direct offering of…
424B5 — Impact 6/10
Jun 30, 2026 Inst.
BlackRock, Inc. — DOUBLED
766,005 shares ($3.0M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 11, 2026
Earnings date
ELTX Q3 2026 Earnings Scheduled — 2026-11-11
Recent
Aug 31, 2026
Press release
Elicio Therapeutics to Participate at the H.C. Wainwright 28th Annual Global Investment Conference
BOSTON, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology…
Aug 24, 2026
Press release
Elicio Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference
BOSTON, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology…
Aug 13, 2026
Earnings
Elicio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
Following the observation of multiple complete responses, Elicio plans to initiate a Phase 1 combination study of ELI-002 7P plus a RAS small…
Aug 5, 2026
Earnings date
ELTX Q2 2026 Earnings Scheduled — 2026-08-05
Jul 2, 2026
Press release
Elicio Therapeutics Announces Pricing of $15 Million Registered Direct Offering
BOSTON, July 02, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), a clinical-stage biotechnology…

SecBot reports

9 filings · 1 press release · 2 bullish · 3 bearish · 4 neutral
All ELTX filing & press-release reports (10)